Juno Therapeutics Inc

Juno Therapeutics — Investor Presentation (September 2016)

19 slides from Juno Therapeutics's investor presentation, Sep 13, 2016

  1. Slide 1: Exhibit 99.1

    Exhibit 99.1

  2. Slide 2: Forward-looking Statements

    Forward-looking Statements This presentation and the accompanying oral commentary contain forward-looking statements that involve risks, uncertainties, and assumptions. If the risks or uncertainties ever materialize or the assumptions prove incorrect, our results may differ materially from those exp

  3. Slide 3: Building the Leading T Cell Company

    Building the Leading T Cell Company Significant advances in CD19-directed product candidates with a go-to-market strategy defined in ALL, NHL, and CLL Moving beyond CD19 target with encouraging data in CD22 and WT-1; more targets and approaches in the clinic Progress with potential best-in-class pro

  4. Slide 4: Compelling Evidence of Rapid Tumor Shrinkage Across Multiple Clinical Trials

    Compelling Evidence of Rapid Tumor Shrinkage Across Multiple Clinical Trials Day 37 After CD19 CAR T Cells ALL Patient Before CD19 CAR T Cells Day 28 After CD19 CAR T Cells NHL Patient Before CD19 CAR T Cells (1)Across two leukemia trials for defined cell products (JCAR014 and JCAR017) in children a

  5. Slide 5: Juno Strategy: Building the Category Winner

    Juno Strategy: Building the Category Winner Win in B-cell Malignancies Balance first-in-class and best-in-class: CD19 (ongoing) CD22 (ongoing) Win in Multiple Myeloma Comparable biology to CD19: BCMA (2017) Other targets (2018+) Win in Virally-mediated Cancers HPV-associated cancers (2017/2018) Othe

  6. Slide 6: CD19 Strategy: Disrupt Leukemia and Lymphoma Today and Disrupt Again

    CD19 Strategy: Disrupt Leukemia and Lymphoma Today and Disrupt Again with Higher Cure Rates Potential First-in-class Potential Best-in-class Next Generation CAR T Smart Combinations JCAR015: focused on high unmet medical need in r/r adult ALL Ongoing Phase II ROCKET trial JCAR017: movement into NHL,

  7. Slide 7: JCAR015: Potential to Transform r/r Adult ALL

    JCAR015: Potential to Transform r/r Adult ALL Phase I data Complete Response / Remission = 82% Complete Molecular Response = 66% Severe Cytokine Release Syndrome (1), (2) = 27% Severe Neurotoxicity (2), (3) = 29% Phase II ROCKET trial Ongoing Goal » to launch as early as 1H2018 Market size Median OS

  8. Slide 8: JCAR017: Building the CD19 Category Winner

    JCAR017: Building the CD19 Category Winner JCAR015 JCAR017 Cells T cells selected Defined composition (1:1 ratio of CD4 / CD8) Manufacturing Key steps automated and functionally closed Plus more naïve and quiescent cells Co-stimulatory domain CD28 4-1BB Goal Transform r/r adult ALL Transform r/r adu

  9. Slide 9: ALL: Defined Cell + 4-1BB + Flu/Cy Conditioning

    ALL: Defined Cell + 4-1BB + Flu/Cy Conditioning JCAR017 Phase 1 Overall Survival(4) 0 60 100 80 40 20 0 6 18 24 Months post T-cell Infusion Overall Survival (%) 12 JCAR014 Phase 1 Overall Survival 0 60 100 80 40 20 0 6 12 18 Time Since CAR T Cell Infusion (Months) Overall Survival (%) JCAR014 with l

  10. Slide 10: NHL: Best-in-class Profile

    Potential to differentiate on efficacy and safety NHL: Best-in-class Profile JCAR014(1),(2) JCAR014 CR = complete response; PR = partial response; ORR = CR + PR; Flu/cy = fludarabine and cyclophosphamide Goal » 2018 approval for JCAR017 (1)At data cutoff date, CRs continue in 70% of patients, rangin

  11. Slide 11: JCAR014: CLL Emerging as a Significant Opportunity

    JCAR014: CLL Emerging as a Significant Opportunity For JCAR014, investigator-reported data as-of May 18, 2016. CR = complete response; PR = partial response; ORR = CR + PR; Flu/cy = fludarabine and cyclophosphamide Conditioning Regimen Flu/Cy(1) Dose Level All Doses N=11 Efficacy CR(2) 5/11 (45%) OR

  12. Slide 12: Platform Goal: Innovation to Increase the Rate of Cures

    Platform Goal: Innovation to Increase the Rate of Cures Next generation CD22: 3 of 3 CMRs at dose level 2 with 3 – 6 month follow-up CD19 / 4-1BB Armored CAR (trial to begin in 2016) Fully-human binding domain (trial to begin in 2016) More approaches to enter the clinic Combinations PD-L1 (2016) A2a

  13. Slide 13: Multiple Myeloma: Follow the Biology

    Multiple Myeloma: Follow the Biology Juno programs BCMA: Juno’s potential competitive advantages Fully-human Soluble vs. non-soluble BCMA Manufacturing Strategies to overcome the tumor microenvironment Other targets 2 additional undisclosed targets B-cell malignancies Multiple myeloma 1. Predictable

  14. Slide 14: Virally-mediated Cancers: Straightforward Solid Organ Tumor Targets

    Virally-mediated Cancers: Straightforward Solid Organ Tumor Targets Identifying and selecting target antigens Viral epitopes that are only on cancer cells, not on healthy tissues Human Papillomavirus (HPV) as an example Targeting tumors caused by HPV 16 and HPV 18 Juno has fully-human, high affinity

  15. Slide 15: Applying CAR & TCRs to Additional Solid Organ Cancers

    Demonstrate that T cells kill cancer – recent checkpoint inhibitor and tumor infiltrating lymphocytes data Demonstrate that T cells home to the tumor Understand and overcome how the tumor microenvironment may be limiting the activity of engineered T cells, and understand how to induce epitope spread

  16. Slide 16: Building a Category Leader

    Building a Category Leader Manufacturing capabilities JuMP facility online Defined cell product Global reach Celgene collaboration - CD19 opt-in JW Therapeutics - investment in China Research capabilities Internal and BD opportunities Strong balance sheet $1.11 billion as of 2Q16 Strong, nimble biot

  17. Slide 17: Manufacturing Infrastructure to Support Patient Supply

    Manufacturing Infrastructure to Support Patient Supply Facility online to supply clinical material for ongoing Phase II ROCKET and Phase I TRANSCEND trials Capacity for thousands of patients with a scalable and modular design Flexible capacity and able to process multiple products Functionally close

  18. Slide 18: Juno's Goals for Value Creation

    Juno’s Goals for Value Creation Execute Leukemia Potential First in Class: JCAR015 Adult ALL Potential Best in Class: JCAR017 Ped and Adult ALL CD19- Disease: JCAR018 (CD22) Human CD19: JCAR021 Transform Lymphoma / CLL JCAR017 (NHL and CLL) JCAR014 PD-L1 Combination Beyond B Cell Malignancies to Mye

  19. Slide 19: Active Programs

    Active Programs Description CD19: JCAR015 (Adult ALL and Adult NHL) Adult ALL Phase I Adult NHL (Post Autologous Tx) Phase I Adult ALL Phase II Pivotal Study CD19: JCAR017 (Pediatric ALL and Adult NHL) Pediatric ALL Phase I / II Adult NHL Phase I CD19: JCAR014 (Adult B Cell Malignancies) Adult B Cel

Juno Therapeutics — Investor Presentation (September 2016) on 6ix